DEFERIPRONE PLUS DEFEROXAMINE VERSUS DEFEROXAMINE IRON CHALATION IN BETA THALASSEMIA MAJOR

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

KARAMI H.; KOSARYAN M.; ABOLGHASEMI H.; RASHIDIGHADER F.; VAHIDSHAHI K.; DABIRIAN M.; KARAMI H.; MAHDAVI M.R.; YOUSEFI E.; ALIZADEH NAVAEI R.; TALE A.; SHAH MOHAMMADI S.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: The Scientific Journal of Iranian Blood Transfusion Year:2011 | Volume:7 | Issue:4 (29) Page(s): 227-234

Download Full-Text

Persian Verion

View:

1,065

Download:

Cites:

Information Journal Paper

Title

DEFERIPRONE PLUS DEFEROXAMINE VERSUS DEFEROXAMINE IRON CHALATION IN BETA THALASSEMIA MAJOR

Author(s)

Keywords

DEFEROXAMINEQ3

DEFERIPRONEQ3

THALASSEMIA MAJORQ3

VENTRICULAR EJECTION FRACTIONQ3

FERRITINSQ3

Abstract

Background and Objectives Iron overload especially in heart is one of the most important causes of death among patients with major thalassemia. Chelation therapy is one of the main therapeutic methods in these patients. This study was done to compare the therapeutic effects of DEFEROXAMINE (DFO) and DEFERIPRONE combination therapy with DEFEROXAMINE alone in the patients of Mazandaran, Iran.Materials and Methods In this clinical trial, major thalassemia patients with serum ferritin>3000 ng/ml were divided into two groups and matched based on age, sex, serum ferritin levels and cardiac systolic function (LVEF). First group received DFO alone and second group received combination therapy of DEFERIPRONE and DEFEROXAMINE. The patients were physically examined every month; serum ferritin, mean Hb, AST, ALT, and LVEF also started to be measured 6 months prior to the study and subsequently at every visit. Data were analyzed using t-test and X² test.Results There were fifty patients in each group in single and combination therapy groups. Duration of F/U was 28.5 ± 6.2 months. Serum ferritin levels in single and combination therapy groups were 4100 ± 1400 and 4500 ± 1700 ng/ml during 6 months before the study, respectively; the levels decreased to 4600 ± 2200 and 3800 ± 1400 ng/ml at the end of treatment, respectively (p<0.05). Only 3 patients had leukopenia and 10 had nausea in combination therapy group.Conclusions The study showed that the combination therapy has a better effect on decreasing the serum level ferritin. Moreover, it can improve LVEF.

Cites

EVALUATION OF GASTRIC SIDE EFFECTS OF NEW FORM OF DEFERIPRONE, (L1; ENTERIC COATED) IN THALASSEMIA MAJOR PATIENTS

References

No record.

Cite

APA: Copy

KARAMI, H., KOSARYAN, M., ABOLGHASEMI, H., RASHIDIGHADER, F., VAHIDSHAHI, K., DABIRIAN, M., KARAMI, H., MAHDAVI, M.R., YOUSEFI, E., ALIZADEH NAVAEI, R., TALE, A., & SHAH MOHAMMADI, S.. (2011). DEFERIPRONE PLUS DEFEROXAMINE VERSUS DEFEROXAMINE IRON CHALATION IN BETA THALASSEMIA MAJOR. THE SCIENTIFIC JOURNAL OF IRANIAN BLOOD TRANSFUSION ORGANIZATION (KHOON), 7(4 (29)), 227-234. SID. https://sid.ir/paper/78766/en

Vancouver: Copy

KARAMI H., KOSARYAN M., ABOLGHASEMI H., RASHIDIGHADER F., VAHIDSHAHI K., DABIRIAN M., KARAMI H., MAHDAVI M.R., YOUSEFI E., ALIZADEH NAVAEI R., TALE A., SHAH MOHAMMADI S.. DEFERIPRONE PLUS DEFEROXAMINE VERSUS DEFEROXAMINE IRON CHALATION IN BETA THALASSEMIA MAJOR. THE SCIENTIFIC JOURNAL OF IRANIAN BLOOD TRANSFUSION ORGANIZATION (KHOON)[Internet]. 2011;7(4 (29)):227-234. Available from: https://sid.ir/paper/78766/en

IEEE: Copy

H. KARAMI, M. KOSARYAN, H. ABOLGHASEMI, F. RASHIDIGHADER, K. VAHIDSHAHI, M. DABIRIAN, H. KARAMI, M.R. MAHDAVI, E. YOUSEFI, R. ALIZADEH NAVAEI, A. TALE, and S. SHAH MOHAMMADI, “DEFERIPRONE PLUS DEFEROXAMINE VERSUS DEFEROXAMINE IRON CHALATION IN BETA THALASSEMIA MAJOR,” THE SCIENTIFIC JOURNAL OF IRANIAN BLOOD TRANSFUSION ORGANIZATION (KHOON), vol. 7, no. 4 (29), pp. 227–234, 2011, [Online]. Available: https://sid.ir/paper/78766/en

Related Journal Papers